Excellent chart.
The Orphan Drug Designation is given to drugs or treatments for "rare," life-threatening diseases. In Europe, a rare disease is defined as one that occurs in less than 5 of every 10,000 people. According to incidence estimates, the prevalence of pancreatic cancer in the European Union is less than 1.5 cases per 10,000 people, a figure significantly below that required for Nuvilex's pancreatic cancer treatment to qualify for the Orphan Drug Designation.
$NVLX
Pistol Pete!